AIVITA Biomedical, Inc.
June 17, 2025
Company Presentation
Oncology
153A
AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. We take a unique pan-antigenic approach for our cancer vaccine — targeting all neoantigens, rather than a select few — allowing our treatment to overcome cancer’s tendency to mutate over time. We are also developing a personalized multi-pathogen vaccine with adaptive immunity against infectious disease.
Our patient-specific treatments in cancer have shown tremendous promise in eradicating tumors without harmful side effects in our melanoma, glioblastoma, and ovarian cancer clinical studies. Our personalized multi-pathogen vaccine demonstrated a 97% T-cell response against the most current strains of COVID-19. Our unique expertise in stem cell growth and directed, high-purity differentiation enables us to develop safe, efficient, and economical manufacturing processes for therapeutic development.
Company HQ City:
Irvine
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
AV-GBM-1 - Autologous DC cancer immunotherapy
CEO
Hans Keirstead, Ph.D.
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Starting our Phase 2/3 clinical trial in GBM. Commercial approvals for multi-pathogen vaccine kit.
What is your next catalyst (value inflection) update?
Q3 2025
Website
www.aivitabiomedical.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}